Shared and specific biological signalling pathways for diabetic retinopathy, peripheral neuropathy and nephropathy by high-throughput sequencing analysis. (23rd August 2022)

• Record Type: Journal Article
• Authors: Zhu, Hui; Chen, Yan-ming; Gong, Wei-kun; Lai, Jing-bo; Yao, Bin-bin; Zhao, Zhi-jia; Lu, Qin-kang; Ye, Ke; Ji, Lin-dan; Xu, Jin
• Is Part Of: Diabetes & vascular disease research. Volume 19:Number 4(2022)
• Publication Date: 2022-08-23
• Subjects: Diabetic retinopathy -- diabetic peripheral neuropathy -- diabetic nephropathy -- mRNA -- long noncoding RNA -- high-throughput sequencing; Diabetic angiopathies -- Periodicals; 616.462005
• DOI: 10.1177/14791641221122918
• Languages: English
• ISSNs: 1479-1641

Abstract

Objectives: We aimed to explore the shared and specific signalling pathways involved in diabetic retinopathy (DR), diabetic peripheral neuropathy (DPN) and diabetic nephropathy (DN). Methods: Differentially expressed mRNAs and lncRNAs were identified by high-throughput sequencing. Subsequently, functional enrichment analysis, protein-protein interaction (PPI) analysis and lncRNAs-mRNAs networks were conducted to determine the pathogenic mechanisms underlying DR, DPN and DN. Results: Twenty-six biological pathways were shared among DR, DPN and DN groups compared to the type 2 diabetes mellitus (T2DM) group without complications, and most of the shared pathways and core proteins were involved in immune and inflammatory responses of microvascular damage. Cytokine‒cytokine receptor interactions and chemokine signalling pathway were the most significant and specific pathways for DR, and the lncRNA‒mRNA regulatory networks affected DR by targeting these pathways. Sphingolipid metabolism and neuroactive ligand-receptor pathways were found to be specific for the pathogenesis of DPN. Moreover, multiple amino acid metabolic pathways were involved in the occurrence and progression of DN. Conclusions: Diabetic retinopathy, DPN and DN exhibited commonality and heterogeneity simultaneously. The shared pathologic mechanisms underlying these diabetic complications are involved in diabetic microvascular damage via immune and inflammatory pathways. Our findings predict several biomarkers and therapeutic targets for these diabetic complications.